Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Read more about Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT).
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Read more about Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. Read more about Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.
Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma. Read more about Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. Read more about Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.
Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Read more about Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Read more about High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Read more about A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Read more about Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale. Read more about Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
